

Azithromycin/favipiravir/hydroxychloroquine

S

Ventricular tachycardia and off-label use: 2 case reports

In a single-centre, cross-sectional study of 75 patients, who had coronavirus disease-2019 (COVID-19), were treated at the University of Health Sciences Samsun Training and Research Hospital, Turkey between 20 March 2020 and 10 April 2020, of whom, two patients [sexes and ages not stated] were described, who developed ventricular tachycardia during off-label treatment with azithromycin and hydroxychloroquine for Covid-19. Additionally, both patients also received off-label treatment with favipiravir for COVID-19 [*dosages, routes, durations of treatments with reactions onsets and outcomes not stated*].

Both patients were diagnosed with COVID-19 and were admitted to an ICU. Subsequently, both patients started receiving off-label treatment with azithromycin, favipiravir and hydroxychloroquine. During ICU admission, both patients developed ventricular tachycardia. Prior to initiation of treatment, both patients had elevated Tp-e intervals and Tp-e/QTc ratios, while QTc intervals were normal. However, after treatment, further increase in Tp-e intervals, Tp-e/QTc ratios and QTc intervals were observed.

Yenercag M, et al. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. *Journal of Electrocardiology* 62: 5-9, Sep-Oct 2020. Available from: URL: <http://doi.org/10.1016/j.jelectrocard.2020.07.005>

803498943